Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
Standard BioTools Inc. (Nasdaq:LAB) announced that CEO Michael Egholm will join a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023, at 3:00 p.m. ET. The event aims to discuss the company's role in advancing human health through innovative technologies. The presentation will be webcast live, with an archived recording available on the company's Investor Relations page. Standard BioTools specializes in mass cytometry and microfluidics technologies, aiding in the swift development of medicines and better patient outcomes.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that President and Chief Executive Officer Michael Egholm, PhD, will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 3:00 p.m. ET.
The presentation will be webcast live and available on the Investor Relations page of the company’s website at Events & Presentations. A recording of the webcast will be archived and available on the Standard BioTools™ Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn®, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, and “Unleashing tools to accelerate breakthroughs in human health” are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Investor Contacts:
Scott R. Greenstone, CFA
ir@standardbio.com
Peter DeNardo
415 389 6400
ir@standardbio.com
FAQ
What is the date of the KeyBanc Capital Markets Investor Forum where LAB's CEO will speak?
What time will the LAB fireside chat start at the investor forum?
Where can I watch the LAB CEO's presentation at the investor forum?
What technologies does Standard BioTools Inc. focus on?
What is the key mission of Standard BioTools Inc. as stated in the press release?
